[go: up one dir, main page]

MXPA02010458A - Peptido modulador del receptor de trombopoyetina. - Google Patents

Peptido modulador del receptor de trombopoyetina.

Info

Publication number
MXPA02010458A
MXPA02010458A MXPA02010458A MXPA02010458A MXPA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A
Authority
MX
Mexico
Prior art keywords
receptor modulating
thrombopoietin receptor
modulating peptide
peptide
thrombopoietin
Prior art date
Application number
MXPA02010458A
Other languages
English (en)
Inventor
Tatjana Naranda
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of MXPA02010458A publication Critical patent/MXPA02010458A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se relaciona a composiciones farmacéuticas y de diagnostico novedosas que facilitan el tratamiento de trombopoyetina.
MXPA02010458A 2000-04-25 2001-04-23 Peptido modulador del receptor de trombopoyetina. MXPA02010458A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108075A EP1149906A1 (en) 2000-04-25 2000-04-25 Thrombopoietin receptor modulating peptide
PCT/EP2001/004553 WO2001080873A2 (en) 2000-04-25 2001-04-23 Thrombopoietin receptor modulating peptide

Publications (1)

Publication Number Publication Date
MXPA02010458A true MXPA02010458A (es) 2003-06-06

Family

ID=8168467

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010458A MXPA02010458A (es) 2000-04-25 2001-04-23 Peptido modulador del receptor de trombopoyetina.

Country Status (24)

Country Link
US (1) US20030181659A1 (es)
EP (2) EP1149906A1 (es)
JP (1) JP2003530867A (es)
KR (1) KR20030009450A (es)
CN (1) CN1426467A (es)
AR (1) AR030278A1 (es)
AU (2) AU2001267366B9 (es)
BG (1) BG107214A (es)
BR (1) BR0110383A (es)
CA (1) CA2407167A1 (es)
CZ (1) CZ20023517A3 (es)
EA (1) EA006423B1 (es)
EE (1) EE200200610A (es)
GE (1) GEP20063763B (es)
HU (1) HUP0300559A3 (es)
IL (1) IL152204A0 (es)
IS (1) IS6582A (es)
MX (1) MXPA02010458A (es)
NO (1) NO20025114L (es)
PL (1) PL358304A1 (es)
SK (1) SK15262002A3 (es)
WO (1) WO2001080873A2 (es)
YU (1) YU79202A (es)
ZA (1) ZA200208662B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039476A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
CA2499625A1 (en) * 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
PL377477A1 (pl) 2002-12-11 2006-02-06 Ferrosan A/S Materiały na bazie żelatyny jako waciki
CN1849141A (zh) * 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
JP2005187435A (ja) * 2003-12-26 2005-07-14 Otsuka Chemical Co Ltd 血小板産生促進組成物
US7923031B2 (en) 2004-01-30 2011-04-12 Ferrosan Medical Devices A/S Haemostatic sprays and compositions
CN101001649B (zh) 2004-07-09 2011-08-31 弗罗桑医疗设备公司 包括透明质酸的止血组合物及其制备方法
US20090004673A1 (en) * 2006-01-31 2009-01-01 Mitsubishi Kagaku Iatron, Inc. Method for Determining Condition of Disseminated Intravascular Coagulation
WO2009109194A2 (en) 2008-02-29 2009-09-11 Ferrosan A/S Device for promotion of hemostasis and/or wound healing
SG195007A1 (en) * 2011-05-13 2013-12-30 Univ Tokyo Polynucleated megakaryocytic cell and method for manufacturing platelets
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
EP3237041B1 (en) 2014-12-24 2020-01-29 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
AU2019266529B2 (en) 2018-05-09 2024-05-23 Ethicon Inc. Method for preparing a haemostatic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1064015A2 (en) * 1998-02-24 2001-01-03 Receptron, Inc. Receptor derived peptides as modulators of receptor activity

Also Published As

Publication number Publication date
AU2001267366B2 (en) 2005-06-30
HUP0300559A3 (en) 2005-09-28
SK15262002A3 (sk) 2003-05-02
GEP20063763B (en) 2006-03-10
WO2001080873A3 (en) 2002-01-31
BG107214A (bg) 2003-11-28
IS6582A (is) 2002-10-14
WO2001080873A2 (en) 2001-11-01
IL152204A0 (en) 2003-05-29
EA006423B1 (ru) 2005-12-29
EP1278849A2 (en) 2003-01-29
JP2003530867A (ja) 2003-10-21
NO20025114L (no) 2002-12-18
CN1426467A (zh) 2003-06-25
PL358304A1 (en) 2004-08-09
CA2407167A1 (en) 2001-11-01
KR20030009450A (ko) 2003-01-29
NO20025114D0 (no) 2002-10-24
AR030278A1 (es) 2003-08-20
YU79202A (sh) 2006-01-16
AU2001267366B9 (en) 2005-07-14
CZ20023517A3 (cs) 2003-10-15
EA200201138A1 (ru) 2003-06-26
AU6736601A (en) 2001-11-07
EP1149906A1 (en) 2001-10-31
HUP0300559A2 (hu) 2003-06-28
ZA200208662B (en) 2003-10-27
EE200200610A (et) 2004-08-16
US20030181659A1 (en) 2003-09-25
BR0110383A (pt) 2003-01-21

Similar Documents

Publication Publication Date Title
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
MXPA02006029A (es) Lipopeptidos novedosos como agentes antibacterianos.
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
MXPA02006028A (es) Lipopeptidos novedosos como agentes antibacterianos.
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
MXPA02006030A (es) Lipopeptidos como agentes antibacterianos.
AU3652102A (en) Compounds and their uses
IL151313A0 (en) Lipase containing pharmaceutical compositions
GB0129260D0 (en) Pharmaceutical compositions and their uses
GR3026758T3 (en) Lactobacillus strains of human origin, their compositions and uses thereof
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
BR9711306A (pt) Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
TNSN04206A1 (en) Novel perindopril salt and pharmaceutical compositions containing same
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
MXPA03010158A (es) Sulfonamidas.
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
DE69831737D1 (de) Neurotrypsin
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
AP2001002369A0 (en) Pharmaceutical complex.
MY138502A (en) Novel alkansulfonamides as endothelin antagonists